SCHEMBL431882

SCHEMBL431882

O=C1N[C@H](C2CCCCC2)CO1

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.34
MGLL Q99685 1/20 0.31
KMT2A Q03164 1/20 0.30
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1440262 1.00 MAPT (0.34) MAPTMGLLKMT2ALMNATSHR
SCHEMBL1439282 0.98 MAPT (0.31) MAPTLMNATSHR
SCHEMBL1439278 0.98 MAPT (0.31) MAPTLMNATSHR
SCHEMBL1439027 0.89
SCHEMBL1439025 0.89
SCHEMBL3412578 0.83 ALDH1A1 (0.33) MAPTLMNATSHR
SCHEMBL9998723 0.82
SCHEMBL1439015 0.82 DAO (0.31)
SCHEMBL1439016 0.82 DAO (0.31)
SCHEMBL16893866 0.79 LMNA (0.30) LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9498483-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2016-11-22 US disclosed
US-9498483-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2016-11-22 US disclosed
US-9498483-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2016-11-22 US disclosed
US-20150224109-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2015-08-13 US disclosed
US-20150224109-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2015-08-13 US disclosed
US-20150224109-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2015-08-13 US disclosed
US-9040690-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2015-05-26 US disclosed
US-9040690-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2015-05-26 US disclosed
US-9040690-B2 2,3,5-trisubstituted thiophene compounds and uses thereof NOVARTIS AG (CH) 2015-05-26 US disclosed
EP-2595983-A1 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF Novartis AG (CH) 2013-05-29 EP disclosed
US-20130123252-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2013-05-16 US disclosed
US-20130123252-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2013-05-16 US disclosed
US-20130123252-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof NOVARTIS AG (CH) 2013-05-16 US disclosed
WO-2012010663-A9 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2013-01-24 WO disclosed
WO-2012010663-A1 2,3,5-TRISUBSTITUTED THIOPHENE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224109-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof TPMT, CYP3A5, CYP11B2 MAPT 2512/4885MGLL 2418/4885KMT2A 4350/4885
US-20130123252-A1 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof TPMT, CYP3A5, CYP11B2 MAPT 2512/4885MGLL 2418/4885KMT2A 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.